Baseline characteristics of patients grouped by gender
| All (N=7785) | Men (n=5596) | Women (n=2189) | P value | |
| Patient characteristics | ||||
| Age, years | 67.6 (±10.7) | 66.3 (±10) | 71.3 (±9.3) | <0.0001 |
| Body mass index (kg/m²) | 25.3 (±3.97) | 25.2 (±3.8) | 25.3 (±4.4) | 0.36 |
| Current smoker (%) | 1674 (21.5) | 1488 (26.6) | 186 (8.5) | <0.0001 |
| Ejection fraction (%) <40 | 650 (9.4) | 523 (10.6) | 127 (6.4) | <0.0001 |
| DM year, median (IQR) | 8 (2–16) | 7 (2–16) | 9 (2–17) | 0.002 |
| History of hypertension (%) | 6410 (82.0) | 4540 (81.1) | 1870 (85.4) | <0.0001 |
| History of MI (%) | 2740 (35.2) | 2169 (38.8) | 571 (26.1) | <0.0001 |
| History of PCI (%) | 3503 (45.0) | 2619 (46.8) | 884 (40.4) | <0.0001 |
| History of CABG (%) | 875 (11.2) | 648 (11.6) | 227 (10.4) | 0.13 |
| History of stroke (%) | 1306 (16.8) | 942 (16.8) | 364 (16.6) | 0.83 |
| History of cancer (%) | 370 (4.8) | 256 (4.6) | 114 (5.2) | 0.24 |
| HR (bpm) | 76 (±14) | 75 (±14) | 77 (±13) | <0.0001 |
| Systolic blood pressure (mm Hg) | 134 (±20) | 133 (±20) | 136 (±21) | <0.0001 |
| Diastolic blood pressure (mm Hg) | 73 (±13) | 74 (±13) | 71 (±12) | <0.0001 |
| LDL-c (mg/dL) | 104 (±33) | 102 (±32) | 107 (±35) | <0.0001 |
| HbA1c, n (%) (mmol/mol) | 7.3 (±1.3) 56 (±14) | 7.2 (±1.3) 55 (±14) | 7.3 (±1.3) 56 (±14) | 0.0002 |
| eGFR (mL/min/1.73 m²) <60 without hemodialysis (%) | 2795 (40.3) | 1871 (37.4) | 924 (47.9) | <0.0001 |
| Medical treatment at discharge (%) | ||||
| Statin | 4963 (63.8) | 3499 (62.5) | 1464 (66.9) | 0.0003 |
| Aspirin | 6879 (88.4) | 4968 (88.8) | 1911 (87.3) | 0.067 |
| Ticlopidine | 2092 (26.9) | 1520 (27.2) | 572 (26.1) | 0.36 |
| Clopidogrel | 2760 (35.5) | 2028 (36.2) | 732 (33.4) | 0.02 |
| Cilostazol | 471 (6.1) | 348 (6.2) | 123 (5.6) | 0.32 |
| Calcium blocker | 3442 (44.2) | 2319 (41.4) | 1123 (51.3) | <0.0001 |
| Beta-blocker | 2978 (38.3) | 2225 (39.8) | 753 (34.4) | <0.0001 |
| Alpha-blocker | 251 (3.2) | 175 (3.1) | 76 (3.5) | 0.44 |
| Angiotensin receptor blocker | 3394 (43.6) | 2375 (42.4) | 1019 (46.6) | 0.001 |
| ACE inhibitors | 1790 (23.0) | 1353 (24.2) | 436 (19.9) | <0.0001 |
| Diuretic | 2149 (27.6) | 1496 (26.7) | 653 (29.8) | 0.0058 |
| Nitrite | 1799 (23.1) | 1273 (22.8) | 526 (24.0) | 0.23 |
| Nicorandil | 2594 (33.3) | 1854 (33.1) | 740 (33.8) | 0.57 |
| Warfarin | 755 (9.7) | 571 (10.2) | 184 (8.4) | 0.016 |
| DOAC | 49 (0.6) | 40 (0.7) | 9 (0.4) | 0.13 |
| Insulin | 1542 (19.8) | 999 (17.9) | 543 (24.8) | <0.0001 |
| Sulfonylurea | 2651 (34.1) | 1912 (34.2) | 739 (33.8) | 0.73 |
| Alpha-glucosidase inhibitor | 1945 (25.0) | 1422 (25.4) | 523 (23.9) | 0.16 |
| Pioglitazone | 1046 (13.4) | 785 (14.0) | 261 (11.9) | 0.019 |
| Biguanide | 1282 (16.5) | 897 (16.0) | 385 (17.6) | 0.09 |
| DPP-4 inhibitor | 1064 (13.7) | 760 (13.6) | 304 (13.9) | 0.72 |
| Glinide | 232 (3.0) | 165 (3.0) | 67 (3.1) | 0.35 |
| GLP-1 receptor agonist | 12 (0.2) | 10 (0.2) | 2 (0.1) | 0.53 |
Data missing: systolic blood pressure 132 (1.7%), LDL-c 556 (7.1%), and HbA1c 423 (5.4%).
Continuous variables available at registration are expressed as mean±SD unless otherwise indicated. Categorical variables are presented as numbers and percentages.
bpm, beats per minute; CABG, coronary artery bypass grafting; DM, diabetes mellitus; DOAC, direct oral anticoagulants; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate; GLP-1, glucagon-like peptide-1; HbA1c, glycosylated hemoglobin A1c; HR, heart rate; LDL-c, low-density lipoprotein cholesterol; MI, myocardial infarction; PCI, percutaneous coronary intervention.